Article Text

Download PDFPDF
Review: erythropoiesis-stimulating agents increase mortality in patients with cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


Do erythropoiesis-stimulating agents (ESAs) used for prevention or treatment of anaemia increase mortality in patients with cancer?

Review scope

Included studies compared ESAs (epoetin or darbepoetin) plus red blood cell (RBC) transfusions as needed with RBC transfusions as needed alone for prevention or treatment of anaemia in patients with cancer. Exclusion criteria were trials of high-dose myeloablative chemotherapy plus stem-cell transplantation, those with planned sample sizes of <100 patients or analyses including <50 patients, or in which >20% of patients had myelodysplastic syndromes or acute leukaemia or used ESAs as preoperative treatment. Outcomes were mortality during active study periods (⩽28 d after end of active period) and overall survival during follow-up.

Review methods

Medline, EMBASE/Excerpta Medica, Cochrane Library, and conference proceedings …

View Full Text


  • Sources of funding: German Federal Ministry of Education and Research; Medical Faculty of University of Cologne; Oncosuisse.